希臘研擬改革以促進臨床研究並提升醫療可近性
Greece Considers Reforms to Boost Clinical Research and Medical Access
截至2026年4月，希臘正將自身定位為崛起中的臨床研究中心。
As of April 2026, Greece is positioning itself as a rising hub for clinical research.
衛生部已實施了大膽的改革，例如1月份的部長令，旨在剔除歷來阻礙進展的官僚繁文縟節。
The Ministry of Health has implemented bold reforms, such as the January Ministerial Decision, aimed at stripping away the bureaucratic red tape that has historically hindered progress.
透過引入標準化合約、透過Mitos國家登錄系統實現流程數位化，並執行嚴格的時間表，政府正在簡化臨床試驗的運作方式。
By introducing standardized contracts, digitizing the process through the Mitos national registry, and enforcing strict timelines, the government is streamlining how clinical trials operate.
這些努力旨在吸引全球投資的同時，也讓希臘病患能更早獲得救命的創新療法。
These efforts intend to attract global investment while granting Greek patients earlier access to life-saving, innovative therapies.
一項新設立的5000萬歐元醫藥創新基金通過在全額報銷前架起了與先進醫藥之間的橋樑，進一步支持了這一使命。
A new €50 million Pharmaceutical Innovation Fund further bolsters this mission by bridging the gap to advanced medicine before full reimbursement.
產業利益相關者，包括希臘醫藥公司協會在內，皆強調持續的財政壓力與備受爭議的「回扣」(clawback)機制，持續繃緊了國家與私人開發商之間的關係。
Industry stakeholders, including the Hellenic Association of Pharmaceutical Companies, highlight that persistent fiscal pressures and the contentious "clawback" system continue to strain the relationship between the state and private developers.
儘管轉向與歐盟一致的數位架構是現代化的重大勝利，但這些倡議的長期成功取決於希臘是否能在有效控制成本與真正鼓勵研發投資的環境之間取得平衡。
While the move toward an EU-aligned, digital framework is a significant victory for modernization, the long-term success of these initiatives depends on whether Greece can balance effective cost-control with an environment that truly encourages R&D investment.
對於希臘而言，這是現代化是否能克服系統性金融挑戰的一項關鍵測驗。
For Greece, it is a critical test of whether modernization can overcome systemic financial challenges.
